|
News For BBY;ADBE;ALXA;BV;ZQK;CYTX From The Last 14 Days Check below for free stories on BBY;ADBE;ALXA;BV;ZQK;CYTX the last two weeks. |
|
|
| May 10, 2013 |
| 10:56 EDT |  | ZQK | T. Rowe Price reports 10.5% passive stake in Quiksilver
|
|
| May 9, 2013 |
| 16:07 EDT |  | CYTX | Cytori Therapeutics reports Q1 EPS (11c), consensus (15c)
 Subscribe for More Information |
|
| May 8, 2013 |
| 12:39 EDT |  | ALXA | Options with increasing implied volatility: ALXA FIO EBIX VMED HNZ
Subscribe for More Information |
|
| 12:07 EDT | | BBY | Stocks with call strike movement; BBY MNST
Best Buy (BBY) June 29 call option implied volatility decreased 2% to 59, Monster Beverage (MNST) May 62.5 call option implied volatility decreased 1% to 64 according to IVolatility. |
|
| 12:06 EDT | | BBY | Stocks with call strike movement; BBY MNST
Subscribe for More Information |
|
| 12:00 EDT |  | ALXA | Alexza Pharmaceuticals rises 23.7%
Alexza Pharmaceuticals is up 23.7%, or $1.03, to $5.37 |
|
| 10:26 EDT |  | ALXA | Alexza deal with Teva could be worth $12 per share or more, says Roth Capital
Subscribe for More Information |
|
| 10:01 EDT | | ALXA | Alexza Pharmaceuticals rises 32.7%
Subscribe for More Information |
|
| 09:06 EDT |  | ALXA | Alexza Pharmaceuticals to host conference call
Subscribe for More Information |
|
| 08:37 EDT | | ZQK | Quiksilver price target raised to $9 from $7 at Stifel
Subscribe for More Information |
| |
| 08:33 EDT | | ALXA | Teva, Alexza announce Teva's license to market Adasuve in the U.S.
Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical (TEVA), and Alexza Pharmaceuticals (ALXA) announced that the companies have entered into an exclusive U.S. license and supply agreement for Adasuve inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all U.S. commercial and clinical activities for Adasuve, including U.S. post-approval clinical studies, and has gained rights to conduct additional clinical trials of Adasuve for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying Adasuve to Teva for commercial sales and clinical trials. Under the terms of the license and supply agreement, Alexza will receive an upfront cash payment of $40M and is eligible to receive up to $195M in additional milestone payments, based upon successful completion of the ADASUVE post-approval studies in the U.S. and achieving net sales targets. In addition, Teva will make tiered, royalty payments based on net commercial sales of Adasuve. |
|
| 08:25 EDT | | ALXA | Alexza Pharmaceuticals trading halted, pending news
Subscribe for More Information |
|
| 07:44 EDT | | BBY | BofA/Merrill's retail analysts hold an analyst/industry conference call
Specialty Retail Analyst Hutchinson provides an update on April monthly sales, earnings and industry trends on an Analyst/Industry conference call. Relevant covered companies BBBY, BBY, BJ, CHS, COH, COST, DG, DLTR, FDO, FL, GPS, KR, KSS, LOW, M, NDN, PLCE, SKS, SWY, TGT, TJX, WMT and ZLC may be included on the Analyst/Industry conference call to be held on May 9 at 1 pm. |
|
| May 7, 2013 |
| 11:39 EDT |  | BBY | Samsung to open mini-shops in 1,400 Best Buy stores, LA Times reports
Subscribe for More Information |
|
| 11:37 EDT | | BBY | Stocks with call strike movement; FSLR BBY
First Solar (FSLR) September 48 call volatility decreased 5% to 55, Best Buy (BBY) June 29 call option implied volatility increased 1% to 57 according to iVolatility. |
|
| 07:10 EDT | | ADBE | Adobe revenue poised to accelerate strongly in FY15, FY16, says Bernstein
Subscribe for More Information |
|
|
|
|
|
